Abstract: Oxygen scavenging barrier polyamide compositions exhibiting high oxygen scavenging capability as well as good coinjection stretch blow moldability characteristics suitable for making multilayer PET bottles with good clarity and delamination resistance are claimed in this invention. The polyamide compositions of this invention comprise a slow crystallizing polyamide blend comprising (i) an amorphous, semiaromatic polyamide homopolymer, copolymer or mixture thereof and (ii) a semicrystalline, aliphatic polyamide homopolymer, copolymer or mixture thereof wherein in the weight ratio of (i):(ii) ranges from about 99:1 to about 30:70; at least one polyamide-compatible, oxidizable polydiene; and at least one oxidation promoting metal salt catalyst. The multilayer PET bottles, made with the polyamide compositions of this invention as the barrier layer, are suitable for extended shelf-life packaging of oxygen-sensitive food and beverage products such as beer and juices.

Abstract: A resin composition comprising the following components (A), (B) and (C), wherein the content of component (A) is from 10 to 90 wt %, component (B):component (C)=from 10:1 to 1:5 (weight ratio), the intrinsic viscosity [&eegr;] is in the range from 0.17 to 0.

Abstract: Process for the preparation of a hydrogenated polymer composed of conjugated diene monomer units and monomer units containing a nitrile group, wherein the hydrogenation is carried out in the presence of hydrazine, an oxidizing compound and a metal compound as catalyst, a metal compound containing a metal atom in an oxidation state of at least 4 being used as catalyst.

Abstract: Heat sensitive substrates, as well as others such as metal or glass, are electrostatically coated with a thermosetting coating powder comprising a melt-mixed, chilled, chipped, and powdered blend of an epoxy resin and a catalyst therefore, and a powdered low temperature curing agent along with conventional additives. The coating powder is deposited on the substrate and heated to fuse, flow and cure. The mixture of resin and catalyst does not cure within the extruder but it is made to cure at low temperatures on the desired substrate by the separate addition of the curing agent to the powdered melt-mixed blend. A small amount of the low temperature curing agent, insufficient to cause substantial curing in the molten stage may be used in place of the catalyst.

Abstract: Novel methods and blends for controlling rheology and transition temperature of photocurable mesogens while maintaining low polymerization shrinkage and without adversely affecting mechanical strength and stability of the cured resins.

Abstract: Ethylene based polymers having high molecular weights can be obtained in high yields at temperatures of industrial interest, by carrying out the polymerization reaction in the presence of catalysts comprising silicon bridged metallocenes having a particular ligand system containing a heteroatom.

Abstract: A process is provided for the preparation of a solid catalyst component for the polymerization of olefins, comprising continuously feeding a liquid containing a titanium compound having at least one titanium-halogen bond into a vessel containing a solid comprising a magnesium halide and continuously discharging liquid from the vessel, whereby the concentration of the solid is maintained within the range of between 80 and 300 g/l, and the product between the average residence time of the liquid in the vessel and the concentration of the solid is maintained below 10,000 min*g/l. An advantage of the process is the reduced time and reactor volume necessary to prepare the catalysts, which show good activity and stereospecificity.

Abstract: 1 A metallocene compound of general formula (I): LGZMXp, wherein L is a divalent group, Z is a moiety of formula (II), wherein R3 and R4 are selected from hydrogen and hydrocarbon groups; A and B are selected from S, O or CR5, wherein R5 is selected from hydrogen and hydrocarbon groups, either A or B being different from CR5; G is a moiety of formula (III), wherein R6, R7, R8 and R9 are selected from hydrogen and hydrocarbon groups, M is an atom of a transition metal, X is selected from a halogen atom, a R10, OR10, OSO2CF3, OCOR10, SR10, NR102 or PR102 group, wherein the substituents R10 is hydrogen and a hydrocarbon group; p is an integer from 0 to 3.

Abstract: A process for the production of an ionic transition metal catalyst in supported form than is highly productive under gas phase olefin polymerization conditions. In the process a an aluminum alkyl is added to a suitable solvent after which a neutral metallocene compound is added to the solution under stirring in a quantity that provides for a ratio of Al to transition metal of at least 25:1. To this metallocene-aluminum alkyl solution is next added an ionic compound the anionic portion of which is a non-coordinating anion under stirring until all materials are dissolve. The ionic compound is added in a quantity that provides for a ratio of NCA to transition metal of at least 1:1. Next the support particles are added to the solution and thereafter the solution is heated to at least 40° C. and held at this elevated temperature for at least 0.5 hour. Thereafter the solvent is removed and the supported catalyst is dried under vacuum.

Abstract: A process for the production of an ionic transition metal catalyst in supported form than is highly productive under gas phase olefin polymerization conditions. In the process a an aluminum alkyl is added to a suitable solvent after which a neutral metallocene compound is added to the solution under stirring in a quantity that provides for a ratio of Al to transition metal of at least 25:1. To this metallocene-aluminum alkyl solution is next added an ionic compound the anionic portion of which is a non-coordinating anion under stirring until all materials are dissolve. The ionic compound is added in a quantity that provides for a ratio of NCA to transition metal of at least 1:1. Next the support particles are added to the solution and thereafter the solution is heated to at least 40° C. and held at this elevated temperature for at least 0.5 hour. Thereafter the solvent is removed and the supported catalyst is dried under vacuum.

Abstract: Alpha-olefins are manufactured in high yield and with very high selectivity by contacting ethylene with an iron complex of a selected 2,6-pyridinedicarboxaldehyde bisimine or a selected 2,6-diacylpyridine bisimine, and in some cases a selected activator compound such as an alkyl aluminum compound. Novel bisimines and their iron complexes are also disclosed. The &agr;-olefins are useful as monomers and chemical intermediates.

Abstract: The invention relates to alkoxysilacycloalkanes, to the process of their preparation and to their use in the polymerization of olefins. The introduction of these alkoxysilacycloalkanes into the olefin polymerization environment makes it possible to raise the heptane-insolubles content of the polymer finally formed.

Abstract: Poly (para-xylylene) (“PPX”) polymer films are processed under particular conditions in order to maintain their stability for use in integrated circuits. This is primarily achieved by controlling the substrate temperature, feed rate of the polymer precursors, and the environmental conditions. The resulting films are stable at high temperatures and compatible with other film layers.

Abstract: A fluorine-containing phenylmaleimide derivative having a specific structure. A polymer obtained by polymerizing monomers containing the derivative. A polymer containing a specific structural unit and having a weight-average molecular weight of 2,000 to 200,000. A chemically amplified resist composition containing the polymer and a photo acid generator, wherein the proportion of the polymer relative to the total of the polymer and the photo acid generator is 70 to 99.8% by mass. A method for pattern formation, which comprises coating the above composition on a to-be-processed substrate, exposing with a light of 180 nm or less wavelength, and conducting baking and development.

Abstract: The instant invention is a method for optimizing material transformation that includes the following six steps. The first step is to identify at least one physical variable that affects performance of a continuous unit operation for the material transformation. The second step is to select an initial set point of the at least one physical variable. The third step is to continuously perform the unit operation to produce a transformed material. The fourth step is to analyze the product to determine at least one component of interest of the transformed material. The fifth step is to select a subsequent set point of the at least one physical variable based on the analysis of the fourth step. The last step is to repeat steps three to five a sufficient number of times to optimize the unit operation.

Abstract: A urethane resin composition for an optoelectric conversion element sealer according to the present invention is a urethane resin composition for an optoelectric conversion element sealer comprising a component (A) containing a compound having isocyanate groups and a component (B) containing a compound having hydroxyl groups, wherein the compound having isocyanate groups is at least one compound selected from the group consisting of an aromatic isocyanate having a structure in which the isocyanate groups are not directly bonded to a benzene ring, an aliphatic isocyanate, an alicyclic isocyanate, and derivatives of these isocyanates.

Abstract: A method for making a bloom-free thermoplastic polyurethane is disclosed. The method entails blending a chain terminator such as monofunctional alkylene alcohol having at least 14 carbon atoms, mono-isocyanate and mono-amine, in a thermoplastic polyurethane that would, but for the blending of the chain terminator of the invention, feature a blooming defect. The polyurethane suitable for the use in the inventive process is the product of a reaction wherein reactants comprise (i) at least one hydroxy functional polyol such as polyester polyol, polyether polyol and polycarbonate polyol, having a number average molecular weight of 500 to 5000 and a hydroxyl functionality of at least 2, (ii) a chain extending compound, and (iii) an organic diisocyanate. The ratio NCO/H characterizing the relative amounts of named reactants is 0.95 to 1.05. The addition of the chain terminator renders the product bloom-free.

Abstract: Novel addition products of isocyanates with oxyalkylene-substituted aminophenol compounds as intermediates for the production of urethane-substituted xanthene colorants, particularly triphenylmethane derivatives such as rhodamines, are provided. The xanthene colorants exhibit improved wax and/or oil solubility and high purity. The urethane-substituted xanthene colorant features very good wax and/or oil solubility, and is believed to be relatively nontoxic. A method for producing this novel colorant is also provided.

Abstract: A lightfast epoxy resin is formed by phosgenating Bisphenol A by reaction with phosgene to produce Bisphenol A bischloroformate. The Bisphenol A bischloroformate is then reacted with either epichlorohydrin, glycidol or pinacol and another chemical to produce a lightfast epoxy resin. By phosgenating the Bisphenol A prior to the reaction with either epichlorohydrin, glycidol or pinacol and another chemical, the resulting epoxy resin has improved lightfastness and is not degraded by sunlight. The epoxy resin of the present invention can be used in paints, coatings, and plastics for vehicles.

Abstract: The present invention provides a kind of liquid crystal aligning film composition used for liquid crystal display (LCD), in which the liquid crystal aligning film composition used for LCD is a polyimide resin oligomer (A) having the structural formula (I) as shown in the following: wherein m is an interger of 1, 2, and 3, R is selected one of from aromatic and cyclicaliphatic, X is selected from the group containing amide, ester, and ether etc., Y is the group of containing cholesterol structure; this polyimide resin oligomer (A) and the second reagent (B) are mixed together, through an induced process (C), to produce a thin film for aligning liquid crystal molecule.

Abstract: The instant invention provides an aromatic polyamide composition for molding which is of superior rigidity, strength, toughness, dimensional stability, resistance to chemicals, external surface appearance and sliding characteristics in high-humidity, high-temperature environments, which has a low coefficient of linear expansion and which is of low warpage.

Abstract: A copolyester having an inherent viscosity of equal to or greater than about 0.3 formed from about 20 to about 60 mole percent based on the amount of aromatic dicarboxylic acid of one or more of isophthalic dicarboxylic acid or an alkyl diester thereof, about 40 to about 80 mole percent based on the amount of aromatic dicarboxylic acid of one or more of terephthalic acid or 2,6-naphthalene dicarboxylic acid or an alkyl diester thereof, about 10 to about 60 mole based on the total amount of dicarboxylic acids of one or more aliphatic dicarboxylic acids or an alkyl diester, about 0.1 to about 5 mole percent based on the moles of total dicarboxylic acid of one or more alkali or alkaline earth metal salts of 5-sulfoisophthalic dicarboxylic acid or an alkyl diester thereof, about 90 to 100 mole percent based on the total amount of glycols of one or more aliphatic glycols, and 0 to about 10 mole percent based on the total amount of glycols of one or more of di(ethylene glycol) and tri(ethylene glycol).

Abstract: The invention is directed to peptides having antimicrobial activity (antimicrobial peptides). The antimicrobial peptides of the present invention are analogs of the Lentivirus Lytic Peptide 1 (LLP1) amino acid sequence. The invention is further directed to peptides referred to as the Lytic Base Unit (LBU) peptides derived from the LLP1 analogs, also having antimicrobial activity. In addition, the present invention is also directed to methods of using the peptides in a variety of contexts, including the treatment or prevention of infectious diseases. The antimicrobial LLP1 analog peptides and the LBU peptides (collectively eLLPs) may be highly active under high salt conditions and in biologic fluids. In addition, the eLLPs are effective when presented either in soluble form, or when attached to a solid surface. Furthermore, the peptides of the present invention are selectively active against a wide variety of bacterial pathogens and exhibit minimal toxicity to eukaryotic cells in vitro and in vivo.

Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.

Abstract: Methods of purifying TGF-&bgr; superfamily proteins, including osteogenic proteins, such as bone morphogenetic proteins (BMPs), are disclosed.

Abstract: The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors.

Abstract: The present invention provides proteins, peptide fragments, nucleic acid molecules and fragments thereof, complementary sequences, allelic forms, homologues, antibodies and variants of SIGLEC-BMS sequences, which are new members of the Sialoadhesin subgroup having protein homology to CD33, and methods of using these molecules.

Abstract: The invention relates to a cell growth and/or differentiation regulatory peptide comprising a sequence of about 9 to about 150 amino acids derived from acetylcholinesterase amino acid sequence, preferably from the C-terminal region of acetylcholinesterase. The invention also relates to pharmaceutical compositions comprising the peptides, particularly for use in promoting survival of stem cells, promoting differentiation of stem cells, promoting growth of stem cells and/or promoting the growth-enhancing effect of a growth factor on stem cells, alone, or in combination with other growth factors. Of particular interest is the use of the peptides in the treatment of thrombocytopenia, post-irradiation conditions, post-chemotherapy conditions, or conditions following massive blood loss and promotion of neural progenitors in use for cell therapies aimed at restoring neural functions in diseased individuals.

Abstract: DNAs encoding bradykinin B1 receptors from mammalian cells have been cloned and characterized. The recombinant receptor is capable of forming receptors which bind des-Arg10 kallidin and other B1-specific ligands. The DNA has been expressed in recombinant host cells which produce active recombinant protein. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The subject invention provides a process for preparing a porous collagen matrix from connective tissue, which comprises treating connective tissue with a solution of hydrogen peroxide and/or an acidic solution so as to obtain a porous collagen matrix.

Abstract: The invention features methods of purifying human serum albumin (hSA) from endogenous serum albumin of the host cell producing the hSA. The methods include providing a sample comprising hSA and serum albumin of the host cell, applying the sample to an affinity column that binds hSA at a higher affinity than the serum albumin of the host cell, eluting bound hSA from the affinity column, and crystallizing the eluted has. The invention also features compositions comprising hSA produced by the methods of the invention.

Abstract: A purification process for large-scale production of Gc-globulin is described. The source of Gc-globulin is preferably a crude plasma fraction but can be any solution, suspension or supernatant containing Gc-globulin, e.g., a milk product, colostrum or a fermentation broth. The Gc-globulin can be plasma-derived or produced by a genetic modified organism. The process includes two key elements: purification by series of ion exchange chromatography steps, and performing at least two virus-reduction steps. A diagnostic method to measure the free Gc-globulin in a patient blood sample, a use of Gc-globulin in medicine and the preparation of a Gc-globulin medicinal product is also provided. The product can be used in therapy for patients with circulatory disorders and complications, i.e., where it is contemplated that said patients would benefit from the administration of Gc-globulin.

Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Abstract: Anthocyanic colorant made of vegetable primary material and process for its production relate to food, cosmetic, pharmaceutical and textile industry and may be used in production of alcoholic and soft drinks, confectionery, products made of sour milk, in coloring of tablet capsules, dying of children's underwear, toys, etc. According to the invention, pelargonidin glycoside was added to the composition of the natural colorant that contained cyanidin glycosides, peonidin glycosides, organic substance and mineral salts. The components percentage shall be as follows, %: cyanidin glycoside 0.1-8.6; peonidin glycoside 0.08-6.45 pelargonidin glycoside 0.005-4.3; organic substance and mineral salts—the rest. Due to the fact that the colorant solution contains pelergonidin glycoside further to cyanidin and peonidin glycosides, the proposed colorant obtained expanded color spectrum. Combination of these three anthocyans in the proposed colorant provides for the most rich spectrum of red colors.

Abstract: The invention provides methods of forcing recombination between polynucleotides. The methods can include the steps of, (a) generating a single strand of a first polynucleotide; (b) generating a single strand of a second polynucleotide, wherein the second polynucleotide is partially complementary to the first polynucleotide; (c) fragmenting the single strand of the first polynucleotide to generate single stranded first polynucleotide fragments; (d) fragmenting the single strand of the second polynucleotide to generate single stranded second polynucleotide fragments; (e) annealing the single stranded first polynucleotide fragments with the single stranded second polynucleotide fragments; and (f) extending the annealed polynucleotide fragments.

Abstract: This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.

Abstract: This invention pertains to genetic libraries encoding enzyme fusion proteins and methods of use to identify a nucleic acid of interest.

Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

Abstract: The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs.

Abstract: The present invention relates to novel human uncoupling polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human uncoupling polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human uncoupling polypeptides.

Abstract: This invention provides methods for the discovery of molecules that target an essential step of bacterial DNA replication—the sealing of DNA strands by NAD+-dependent DNA ligase. Specific structural components of NAD+-dependent DNA ligase that are important for the reaction of DNA ligase with NAD+ and that comprise a putative binding site for the NMN component of NAD+ were identified. The invention also includes recombinant DNA ligase enzymes that are defective in their reaction with NAD+, but active in the ligation of pre-adenylated DNA nicks. An underlying principle of this invention is the use of NAD+-reactive and NAD+-defective ligases to identify molecules that specifically bind to the NAD+-binding site of DNA ligase and thereby interfere with the reaction of DNA ligase with NAD+.

Abstract: Methods for isolating K+Hnov genes are provided. The K+Hnov nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

Abstract: Oligomers which have substituents on the 2′ position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.

Abstract: The present invention relates to novel processes for the preparation of 3-methylenecephams. More specifically, the present invention relates in part to the intramolecular cyclization of penicillin sulfoxide derived monocyclic azetidinone derivatives either thermally or with lanthanide metal salt catalysts.

Abstract: The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety.

Abstract: Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

Abstract: Compounds of the formula 1

Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains.